Related Experiment Video

Updated: May 18, 2026

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry
06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry

Published on: November 23, 2011

Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary

Peter W Stacpoole1, Ton J deGrauw, Annette S Feigenbaum

  • 1University of Florida, USA. pws@ufl.edu

Mitochondrion
|October 2, 2012
PubMed

Insights

This Phase 3 trial investigates CoenzymeQ₁₀ (CoQ₁₀) for children with genetic mitochondrial diseases. Challenges include existing CoQ₁₀ use and trial participation skepticism, hindering therapy evaluation.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Genetic mitochondrial diseases are life-threatening inborn errors of energy metabolism.
  • CoenzymeQ₁₀ (CoQ10) is often used empirically for mitochondrial disease, complicating clinical trials.
  • Skepticism exists regarding placebo-controlled trials in the mitochondrial disease community.

Purpose of the Study:

  • To report the design and implementation of the first Phase 3 trial of CoenzymeQ₁₀ (CoQ₁₀) in pediatric patients with genetic mitochondrial diseases.
  • To establish rigorous eligibility criteria for the trial.
  • To address challenges in patient recruitment for the trial.

Main Methods:

  • A Phase 3 clinical trial was designed and implemented.
  • Novel and rigorous eligibility criteria were established.
  • Patient recruitment strategies are ongoing.

Main Results:

  • The trial is currently open to recruitment.
  • Significant challenges to patient recruitment have been identified.
  • Barriers include widespread empiric CoQ₁₀ use and community skepticism towards placebo-controlled trials.

Conclusions:

  • The trial aims to ethically and scientifically evaluate CoQ₁₀ for mitochondrial diseases.
  • Overcoming recruitment barriers is crucial for approving new therapies.
  • Further research is needed to validate nutritional and pharmacological interventions for these rare genetic disorders.

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Quantification of Coenzyme A in Cells and Tissues08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Related Concept Videos

Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cofactors and Coenzymes01:27

Cofactors and Coenzymes

Enzymes require additional components for proper function. There are two such classes of molecules: cofactors and coenzymes. Cofactors are metallic ions and coenzymes are non-protein organic molecules. Both of these types of helper molecule can be tightly bound to the enzyme or bound only when the substrate binds.
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...